U.S. Clinical Oncology Next Generation Sequencing (NGS) Market Size & Forecast By Technology (Whole Genome Sequencing, Whole Exon Sequencing, Targeted Sequencing & Resequencing), By Workflow (NGS Pre-Sequencing, Sequencing, NGS Data Analysis, Primary, Secondary & Tertiary Data Analysis), By End Use (Academic & Clinical Research, Hospitals & Clinics, Pharma & Biotech Entities) And Trend Analysis From 2013 To 2024

Published: Oct, 2016 | Pages: 86 | Publisher: Grand View Research
Industry: Biotechnology | Report Format: Electronic (PDF)

U.S. clinical oncology next generation sequencing market is anticipated to reach USD 1.53 billion by 2024, according to a new report by Grand View Research, Inc. Application of NGS platform for clinical oncology are expected to grow at a steady pace under the influence of increasing adoption of NGS platforms in oncology R&D coupled with rising incidents of cancer.

Application of NGS based cancer diagnostics for screening and monitoring of oncogenes to understand the underlying mechanism behind causes of cancer is expected to boost growth of this vertical throughout the forecast period.

Moreover, exponentially decreasing costs for sequencing have also spurred the demand for NGS platform in clinical oncology research as whole genome analysis has become affordable even by the smaller R&D entities. In addition, high competition amongst prominent market players to enhance their share in the market is also expected to translate into increased revenues generated by these companies as a result.

Further key findings from the report suggest:

Out of the different technologies offered by NGS platforms, targeted sequencing & resequencing accounted for the largest share owing to the fact that it enables study of changes in diseases at molecular level, & analyze the underlying modifications in the genetic sequence to investigate epigenomics of cancer, thus enhancing demand for more advancement in targeted sequencing tools.

Workflow associated with genomic sequencing is expected to witness lucrative progress as a result of variation in platforms provided by prominent market players with respect to amount of DNA sequenced per cycle, read length, and runtime. Furthermore, data analysis of raw sequence data thus obtained, is the most critical step in the workflow of NGS, and is thus anticipated to experience immense growth in coming years as a consequence of abundance of data generated post sequencing.

Adoption of high throughput sequencing platform by clinical sector is observed to be more promising for NGS based oncology research market as a consequence of usage of NGS in cancer research and more specifically in discovery of new cancer related genes, tumor heterogeneity, and identification of alterations that are contributive in tumorogenesis

Key players operating in this industry include Illumina Inc., Roche, Agilent Technologies, Knome Incorporated. Genomatix Software GmbH, GATC Biotech Ag, Oxford Nanopore Technologies Ltd, Macrogen Inc., Life technologies Corp, DNASTAR Inc, Exosome Diagnostics, Biomatters Ltd, CLC Bio, BGI, Qiagen NV, Perkin Elmer, Incorporated, Pacific Bioscience, Inc, Partek, Inc, GnuBIO, Foundation Medicine, Paradigm, Caris Life Sciences and Myriad Genetics and they are actively engaged in manufacturing and commercialization of innovative bioinformatics algorithms as demonstrated by the increasingly growing number of partnerships between prominent players and emerging players.

For instance, In February 2016, Thermo Fisher collaborated with Invivoscribe Technologies, Inc for the development of NGS based, in vitro diagnostic (IVD) oncology tests on Ion PGM Dx System which is further anticipated to accelerate growth of the company in near future. Similarly, in June 2016, Thermo Fisher supported enhancement and commercialization of clinical research assay and in vitro diagnostics using NGS technology launched the Ion Torrent Developers Alliance Program.

 Table of Contents

Chapter 1 Research Methodology
                   1.1 Information procurement
                   1.2 Data Analysis

Chapter 2 Executive Summary
                   2.1 U.S.
                      2.1.1 U.S. next generation sequencing market, 2013 - 2024 (USD Million)

Chapter 3 Market Snapshot

Chapter 4 Market Variables, Trends & Scope
                   4.1 Market segmentation& scope
                      4.1.1 Market Driver Analysis
                            4.1.1.1 Exponentially decreasing costs for genetic sequencing
                            4.1.1.2 Growing related advancement of personalized medicine
                            4.1.1.3 Rise in competition amongst prominent market entities
                            4.1.1.4 Growing healthcare expenditure triggering development of effective PM diagnostic & therapeutic procedure for cancer
                            4.1.1.5 Increasing prevalence of cancer
                            4.1.1.6 Growing adoption of NGS over single gene testing
                      4.1.2 Market Restraint Analysis
                            4.1.2.1 Lack of computational efficiency for data management
                            4.1.2.2 Non-value based NGS reimbursement policy
                   4.2 Penetration & growth prospect mapping for applications, 2015
                   4.3 Penetration & growth prospect mapping for prominent industry players, 2015
                   4.4 NGS platform positioning, 2015
                   4.5 U.S. clinical oncology NGS company market share analysis, 2015
                   4.6 Next Generation Sequencing - SWOT Analysis, By Factor (political & legal, economic and technological)
                   4.7 Industry Analysis - Porter's
                   4.8 Upcoming Developments Analysis in Oncology NGS

Chapter 5 Market Categorization 1: Technology Estimates & Trend Analysis
                   5.1 U.S. clinical oncology NGSmarket: Technology movement analysis
                   5.2 Targeted Sequencing & Resequencing
                      5.2.1 U.S. targeted sequencing & resequencingmarket, 2013 - 2024 (USD Million)
                   5.3 Whole Genome Sequencing
                      5.3.1 U.S. whole genome sequencingmarket, 2013 - 2024 (USD Million)
                   5.4 Whole Exome Sequencing
                      5.4.1 U.S. whole exomesequencing market, 2013 - 2024 (USD Million)

Chapter 6 Market Categorization 2: Workflow Estimates & Trend Analysis
                   6.1 U.S. clinical oncology NGS market: Workflow movement analysis
                   6.2 NGS Pre-Sequencing
                      6.2.1 U.S.NGS pre-sequencingmarket, 2013 - 2024 (USD Million)
                   6.3 NGS Sequencing
                      6.3.1 U.S.NGS sequencingmarket, 2013 - 2024 (USD Million)
                   6.4 NGS Data Analysis
                      6.4.1 U.S. NGS data analysis2013 - 2024 (USD Million)
                      6.4.2 NGS Primary Data Analysis
                            6.4.2.1 U.S.NGS primary data analysis market, 2013 - 2024 (USD Million)
                      6.4.3 NGS Secondary Data Analysis
                            6.4.3.1 U.S.NGS secondary data analysis, 2013 - 2024 (USD Million)
                      6.4.4 NGS Tertiary Data Analysis
                            6.4.4.1 U.S.NGS tertiary data analysisservices market, 2013 - 2024 (USD Million)

Chapter 7 Market Categorization 3: End-use Estimates & Trend Analysis
                   7.1 U.S. Clinical Oncology NGSmarket: End-use movement analysis
                   7.2 Academic Research
                      7.2.1 U.S.academic researchmarket, 2013 - 2024 (USD Million)
                   7.3 Clinical Research
                      7.3.1 U.S.clinical researchmarket, 2013 - 2024 (USD Million)
                   7.4 Hospitals & Clinics
                      7.4.1 U.S.hospitals & clinics market2013 - 2024 (USD Million)
                   7.5 Pharma & Biotech Entities
                      7.5.1 U.S.pharma & biotech entitiesmarket, 2013 - 2024 (USD Million)
                   7.6 Other users
                      7.6.1 U.S.other usersmarket, 2013 - 2024 (USD Million)

Chapter 8 Market Categorization 4: Regional Estimates & Trend Analysis, by Technology, Workflow&End-use

Chapter 9 Competitive Landscape
                   9.1 Strategy framework
                   9.2 Market participation categorization
                   9.3 Company Profiles
                      9.3.1 Illumina Incorporated
                            9.3.1.1 Company Overview
                            9.3.1.2 Financial Performance
                            9.3.1.3 Product Benchmarking
                            9.3.1.4 Strategic Initiatives
                      9.3.2 Roche Sequencing (454 Life Sciences)
                            9.3.2.1 Company Overview
                            9.3.2.2 Financial Performance
                            9.3.2.3 Product Benchmarking
                            9.3.2.4 Strategic Initiatives
                      9.3.3 Agilent Technologies
                            9.3.3.1 Company Overview
                            9.3.3.2 Financial Performance
                            9.3.3.3 Product Benchmarking
                            9.3.3.4 Strategic Initiatives
                      9.3.4 Knome Inc.
                            9.3.4.1 Company Overview
                            9.3.4.2 Financial Performance
                            9.3.4.3 Product Benchmarking
                            9.3.4.4 Strategic Initiatives
                      9.3.5 Genomatix Software GmbH
                            9.3.5.1 Company Overview
                            9.3.5.2 Financial Performance
                            9.3.5.3 Product Benchmarking
                            9.3.5.4 Strategic Initiatives
                      9.3.6 GATC Biotech Ag
                            9.3.6.1 Company Overview
                            9.3.6.2 Financial Performance
                            9.3.6.3 Product Benchmarking
                            9.3.6.4 Strategic Initiatives
                      9.3.7 Oxford Nanopore Technologies Ltd.
                            9.3.7.1 Company Overview
                            9.3.7.2 Financial Performance
                            9.3.7.3 Product Benchmarking
                            9.3.7.4 Strategic Initiatives
                      9.3.8 Macrogen Inc.
                            9.3.8.1 Company Overview
                            9.3.8.2 Financial Performance
                            9.3.8.3 Product Benchmarking
                            9.3.8.4 Strategic Initiatives
                      9.3.9 Life Technologies Corp.
                            9.3.9.1 Company Overview
                            9.3.9.2 Financial Performance
                            9.3.9.3 Product Benchmarking
                            9.3.9.4 Strategic Initiatives
                      9.3.10 DNASTAR Inc.
                            9.3.10.1 Company Overview
                            9.3.10.2 Financial Performance
                            9.3.10.3 Product Benchmarking
                            9.3.10.4 Strategic Initiatives
                      9.3.11 Myriad Genetics
                            9.3.11.1 Company Overview
                            9.3.11.2 Financial Performance
                            9.3.11.3 Product Benchmarking
                            9.3.11.4 Strategic Initiatives
                      9.3.12 Exosome Diagnostics, Inc.
                            9.3.12.1 Company Overview
                            9.3.12.2 Financial Performance
                            9.3.12.3 Product Benchmarking
                            9.3.12.4 Strategic Initiatives
                      9.3.13 Biomatters Ltd.
                            9.3.13.1 Company Overview
                            9.3.13.2 Financial Performance
                            9.3.13.3 Product Benchmarking
                            9.3.13.4 Strategic Initiatives
                      9.3.14 Life CLC Bio
                            9.3.14.1 Company Overview
                            9.3.14.2 Financial Performance
                            9.3.14.3 Product Benchmarking
                            9.3.14.4 Strategic Initiatives
                      9.3.15 BGI (Complete Genomics)
                            9.3.15.1 Company Overview
                            9.3.15.2 Financial Performance
                            9.3.15.3 Product Benchmarking
                            9.3.15.4 Strategic Initiatives
                      9.3.16 Qiagen NV
                            9.3.16.1 Company Overview
                            9.3.16.2 Financial Performance
                            9.3.16.3 Product Benchmarking
                            9.3.16.4 Strategic Initiatives
                      9.3.17 Perkin Elmer, Inc.
                            9.3.17.1 Company Overview
                            9.3.17.2 Financial Performance
                            9.3.17.3 Product Benchmarking
                            9.3.17.4 Strategic Initiatives
                      9.3.18 Pacific Bioscience, Inc.
                            9.3.18.1 Company Overview
                            9.3.18.2 Financial Performance
                            9.3.18.3 Product Benchmarking
                            9.3.18.4 Strategic Initiatives
                      9.3.19 Partek, Inc.
                            9.3.19.1 Company Overview
                            9.3.19.2 Financial Performance
                            9.3.19.3 Product Benchmarking
                            9.3.19.4 Strategic Initiatives
                      9.3.20 GnuBIO (Bio-Rad)
                            9.3.20.1 Company Overview
                            9.3.20.2 Financial Performance
                            9.3.20.3 Product Benchmarking
                            9.3.20.4 Strategic Initiatives
                      9.3.21 Foundation Medicine Inc.
                            9.3.21.1 Company Overview
                            9.3.21.2 Financial Performance
                            9.3.21.3 Product Benchmarking
                            9.3.21.4 Strategic Initiatives
                      9.3.22 Paradigm Diagnostics, Inc
                            9.3.22.1 Company Overview
                            9.3.22.2 Financial Performance
                            9.3.22.3 Product Benchmarking
                            9.3.22.4 Strategic Initiatives
                      9.3.23 Caris Life Sciences
                            9.3.23.1 Company Overview
                            9.3.23.2 Financial Performance
                            9.3.23.3 Product Benchmarking
                            9.3.23.4 Strategic Initiatives

List of Tables

TABLE 1 Healthcare expenditure levels, 2012
TABLE 2 North America cancer incidences in 2012
TABLE 3 U.S. clinical oncology NGS market estimates, by technology, 2013 - 2015 (USD Million)
TABLE 4 U.S. clinical oncology NGS market forecasts, by technology, 2016 - 2024 (USD Million)
TABLE 5 U.S. clinical oncology NGS market estimates, by workflow, 2013 - 2015 (USD Million)
TABLE 6 U.S. clinical oncology NGS market forecasts, by workflow, 2016 - 2024 (USD Million)
TABLE 7 U.S. clinical oncology NGS data analysis market estimates, by workflow, 2013 - 2015 (USD Million)
TABLE 8 U.S. clinical oncology NGS data analysis market forecasts, by workflow, 2016 - 2024 (USD Million)
TABLE 9 U.S. clinical oncology NGS market estimates, by end use, 2013 - 2015 (USD Million)
TABLE 10 U.S. clinical oncology NGS market forecasts, by end use, 2016- 2024 (USD Million)